Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Hocková D, Holý A, Masojídková M, Keough DT, de Jersey J, Guddat LW.

Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. doi: 10.1016/j.bmc.2009.07.044. Epub 2009 Jul 25.

PMID:
19666228
2.

Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.

Krečmerová M, Dračínský M, Hocková D, Holý A, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Feb 1;20(3):1222-30. doi: 10.1016/j.bmc.2011.12.034. Epub 2011 Dec 30.

PMID:
22249123
3.

Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.

Hocková D, Keough DT, Janeba Z, Wang TH, de Jersey J, Guddat LW.

J Med Chem. 2012 Jul 12;55(13):6209-23. doi: 10.1021/jm300662d. Epub 2012 Jun 22.

PMID:
22725979
4.

Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW.

Bioorg Med Chem. 2012 Jan 15;20(2):1076-89. doi: 10.1016/j.bmc.2011.11.034. Epub 2011 Dec 1.

PMID:
22178188
5.

Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.

Keough DT, Hocková D, Holý A, Naesens LM, Skinner-Adams TS, Jersey Jd, Guddat LW.

J Med Chem. 2009 Jul 23;52(14):4391-9. doi: 10.1021/jm900267n.

PMID:
19527031
6.

The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.

Baszczyňski O, Hocková D, Janeba Z, Holý A, Jansa P, Dračínský M, Keough DT, Guddat LW.

Eur J Med Chem. 2013 Sep;67:81-9. doi: 10.1016/j.ejmech.2013.06.032. Epub 2013 Jun 22.

PMID:
23850568
7.

Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Clinch K, Crump DR, Evans GB, Hazleton KZ, Mason JM, Schramm VL, Tyler PC.

Bioorg Med Chem. 2013 Sep 1;21(17):5629-46. doi: 10.1016/j.bmc.2013.02.016. Epub 2013 Mar 5.

PMID:
23810424
8.

Synthesis and Evaluation of Novel Acyclic Nucleoside Phosphonates as Inhibitors of Plasmodium falciparum and Human 6-Oxopurine Phosphoribosyltransferases.

Kaiser MM, Hocková D, Wang TH, Dračínský M, Poštová-Slavětínská L, Procházková E, Edstein MD, Chavchich M, Keough DT, Guddat LW, Janeba Z.

ChemMedChem. 2015 Oct;10(10):1707-23. doi: 10.1002/cmdc.201500322. Epub 2015 Aug 25.

PMID:
26368337
9.

Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.

Keough DT, Skinner-Adams T, Jones MK, Ng AL, Brereton IM, Guddat LW, de Jersey J.

J Med Chem. 2006 Dec 14;49(25):7479-86.

PMID:
17149876
10.

Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity.

Keough DT, Špaček P, Hocková D, Tichý T, Vrbková S, Slavětínská L, Janeba Z, Naesens L, Edstein MD, Chavchich M, Wang TH, de Jersey J, Guddat LW.

J Med Chem. 2013 Mar 28;56(6):2513-26. doi: 10.1021/jm301893b. Epub 2013 Mar 19.

PMID:
23448281
11.

Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents.

Keough DT, Hocková D, Janeba Z, Wang TH, Naesens L, Edstein MD, Chavchich M, Guddat LW.

J Med Chem. 2015 Jan 22;58(2):827-46. doi: 10.1021/jm501416t. Epub 2014 Dec 24.

PMID:
25494538
12.

Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme.

Keough DT, Ng AL, Winzor DJ, Emmerson BT, de Jersey J.

Mol Biochem Parasitol. 1999 Jan 5;98(1):29-41.

PMID:
10029307
13.

Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy.

Keough DT, Hocková D, Krecmerová M, Cesnek M, Holý A, Naesens L, Brereton IM, Winzor DJ, de Jersey J, Guddat LW.

Mol Biochem Parasitol. 2010 Oct;173(2):165-9. doi: 10.1016/j.molbiopara.2010.05.018. Epub 2010 Jun 1.

PMID:
20595032
14.

Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Hazleton KZ, Ho MC, Cassera MB, Clinch K, Crump DR, Rosario I Jr, Merino EF, Almo SC, Tyler PC, Schramm VL.

Chem Biol. 2012 Jun 22;19(6):721-30. doi: 10.1016/j.chembiol.2012.04.012.

PMID:
22726686
15.

6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.

de Jersey J, Holý A, Hocková D, Naesens L, Keough DT, Guddat LW.

Curr Top Med Chem. 2011;11(16):2085-102. Review.

PMID:
21619515
16.

Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.

Gardiner DL, Skinner-Adams TS, Brown CL, Andrews KT, Stack CM, McCarthy JS, Dalton JP, Trenholme KR.

Expert Rev Anti Infect Ther. 2009 Nov;7(9):1087-98. doi: 10.1586/eri.09.93. Review.

PMID:
19883329
17.
18.

Rational design of selective submicromolar inhibitors of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Aronov AM, Munagala NR, Ortiz De Montellano PR, Kuntz ID, Wang CC.

Biochemistry. 2000 Apr 25;39(16):4684-91.

PMID:
10769124
19.

Evidence for multiple active states of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.

Sujay Subbayya IN, Balaram H.

Biochem Biophys Res Commun. 2000 Dec 20;279(2):433-7.

PMID:
11118304
20.

Targeting Plasmodium falciparum purine salvage enzymes: a look at structure-based drug development.

Donaldson T, Kim K.

Infect Disord Drug Targets. 2010 Jun;10(3):191-9. Review.

PMID:
20480551

Supplemental Content

Support Center